Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally A

Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT07750951 by Xijing Hospital, with a registry enrolment figure of 34 participants, started 2026-05-29 and due to reach its primary completion in 2026-11. Interventions recorded: Cindilimab、IBI310、Capecitabine、Oxaliplatin. Conditions listed: MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma. Primary outcome: Pathological complete response (PCR) rate. Colorectal eligibility wording from the registry: "* 4\) The primary lesion is a locally advanced rectal adenocarcinoma with histopathologically confirmed MSI-H/dMMR characteristics". Sites: China. No results are recorded here; the registry entry is the source.